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Compounds containing guanidine-related molecules
have been used since medieval times to relieve symp-
toms of diabetes mellitus. Guanidine itself was too toxic
but two linked guanidine rings (biguanides) were useful
and generally safer. For 20 years, phenformin was used
before adverse effects led to removal from the US and
European markets. Metformin continues to be widely
prescribed for diabetes treatment and is associated with
improved survival compared to other diabetes drugs.
With the current interest in using the more potent
phenformin for cancer therapy, it is timely to review the
risks, benefits, and potential contraindications.
The adipose cell is as an endocrine organ in addition to
its role in energy storage. Adipocytes secrete hormones,
cytokines and other factors that influence energy balance,
glucose homeostasis, insulin sensitivity and vascular biol-
ogy. In humans with obesity and type 2 diabetes, expression
of the Glut4 glucose transporter is down-regulated selec-
tively in adipocytes resulting in systemic insulin resistance.
Knocking out Glut4 selectively in adipocytes in mice
increases the risk of diabetes while adipose-specific Glut4
overexpression confers enhanced glucose tolerance in spite
of increased adiposity. To understand how adipocytes regu-
late glucose homeostasis and insulin sensitivity, we per-
formed DNA microarray analysis of adipose tissue from
mice with adipose-specific knockdown or overexpression of
Glut4. The most highly reciprocally regulated gene is nico-
tinamide N-methyltransferase (Nnmt). NNMT methylates
nicotinamide (vitamin B3) using S-adenosylmethionine
(SAM) as a methyl donor. Nicotinamide is a precursor for
NAD
+, an important cofactor linking cellular redox states
with energy metabolism. NNMT expression is increased in
adipose tissue and liver of obese and diabetic mice. Further-
more, NNMT knockdown in adipose tissue and liver using
anti-sense oligonucleotides in mice on a high fat diet,
protects against diet-induced obesity by augmenting cellu-
lar energy expenditure. This involves a novel mechanism
which could provide new strategies for prevention and
treatment of obesity and type 2 diabetes. Since NNMT is
also elevated in many cancers, NNMT knockdown could
be beneficial for cancer prevention and/or treatment.
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